Hims & Hers’ earnings soar while GLP-1 drug crisis deepens—what this means for investors

Pallavi Madhiraju- November 5, 2024 0

Hims & Hers Health Inc. saw its stock surge following a robust quarterly earnings report, which showcased significant growth in revenue and subscriber numbers. Despite ... Read More

Novo Nordisk stock climbs 1.52% as obesity drug Liraglutide shows promise in young kids

Pallavi Madhiraju- September 11, 2024 0

Novo Nordisk A/S shares climbed by 1.52% today to 888.60 DKK, following the release of promising new data on its obesity drug Liraglutide, which has ... Read More

Biocon and Juno Pharmaceuticals ink game-changing diabetes drug deal

Pallavi Madhiraju- October 7, 2023 0

Biocon Limited, the innovation-driven global biopharmaceutical frontrunner, has made headlines by sealing a significant partnership agreement with Juno Pharmaceuticals, Canada's esteemed specialty pharmaceutical giant. This ... Read More

Biocon partners with Zentiva for European marketing of Liraglutide

Pallavi Madhiraju- November 29, 2022 0

Biocon Limited has entered into a semi-exclusive partnership with Zentiva, a Czech pharma company for marketing its drug-device combination Liraglutide for the treatment and management ... Read More

Novo Nordisk gets Saxenda FDA updated label to cover obesity treatment in adolescents

pharmanewsdaily- December 6, 2020 0

Novo Nordisk has been given approval from the US Food and Drug Administration (FDA) for an updated label for Saxenda (liraglutide) injection 3 mg for ... Read More

Scientists identify drug for obese people to lose weight by reducing appetite

pharmanewsdaily- June 4, 2018 0

Good news for all the obese people who want to lose weight as scientists found a new drug that could help genetically obese persons to ... Read More